GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Additional Paid-In Capital

MorphoSys AG (XSWX:MOR) Additional Paid-In Capital : CHF884.7 Mil(As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Additional Paid-In Capital?


MorphoSys AG's quarterly additional paid-in capital declined from Jun. 2023 (CHF821.5 Mil) to Sep. 2023 (CHF0.0 Mil) but then increased from Sep. 2023 (CHF0.0 Mil) to Dec. 2023 (CHF884.7 Mil).

MorphoSys AG's annual additional paid-in capital declined from Dec. 2021 (CHF867.2 Mil) to Dec. 2022 (CHF822.8 Mil) but then increased from Dec. 2022 (CHF822.8 Mil) to Dec. 2023 (CHF884.7 Mil).

MorphoSys AG Additional Paid-In Capital Historical Data

The historical data trend for MorphoSys AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Additional Paid-In Capital Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 685.83 809.48 867.22 822.76 884.69

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 822.76 826.95 821.55 - 884.69

MorphoSys AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

MorphoSys AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (XSWX:MOR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:FYB XTER:HPHA XTER:MDG1 XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX OCSE:GMAB ALNY BGNE BMRN RPRX SRPT
Traded in Other Exchanges
MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria
Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
Website
https://www.morphosys.com
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.